Belzutifan special drug use results survey in radically unresectable or metastatic renal cell carcinoma: a postauthorization safety study (PASS) (MK-6482-045) First published 20/02/2026 Last updated 20/02/2026 EU PAS number:EUPAS1000000880 Study Planned